These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Nishino S; Sakurai E; Nevsimalova S; Yoshida Y; Watanabe T; Yanai K; Mignot E Sleep; 2009 Feb; 32(2):175-80. PubMed ID: 19238804 [TBL] [Abstract][Full Text] [Related]
3. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. Oka Y; Inoue Y; Kanbayashi T; Kuroda K; Miyamoto M; Miyamoto T; Ikeda A; Shimizu T; Hishikawa Y; Shibasaki H Sleep; 2006 Nov; 29(11):1439-43. PubMed ID: 17162990 [TBL] [Abstract][Full Text] [Related]
4. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Andlauer O; Moore H; Hong SC; Dauvilliers Y; Kanbayashi T; Nishino S; Han F; Silber MH; Rico T; Einen M; Kornum BR; Jennum P; Knudsen S; Nevsimalova S; Poli F; Plazzi G; Mignot E Sleep; 2012 Sep; 35(9):1247-55F. PubMed ID: 22942503 [TBL] [Abstract][Full Text] [Related]
5. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Knudsen S; Jennum PJ; Alving J; Sheikh SP; Gammeltoft S Sleep; 2010 Feb; 33(2):169-76. PubMed ID: 20175400 [TBL] [Abstract][Full Text] [Related]
8. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Mignot E; Lammers GJ; Ripley B; Okun M; Nevsimalova S; Overeem S; Vankova J; Black J; Harsh J; Bassetti C; Schrader H; Nishino S Arch Neurol; 2002 Oct; 59(10):1553-62. PubMed ID: 12374492 [TBL] [Abstract][Full Text] [Related]
9. Traditional biomarkers in narcolepsy: experience of a Brazilian sleep centre. Coelho FM; Pradella-Hallinan M; Pedrazzoli M; Soares CA; Fernandes GB; Gonçalves AL; Tufik S; Bittencourt LR Arq Neuropsiquiatr; 2010 Oct; 68(5):712-5. PubMed ID: 21049180 [TBL] [Abstract][Full Text] [Related]
10. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Heier MS; Evsiukova T; Vilming S; Gjerstad MD; Schrader H; Gautvik K Sleep; 2007 Aug; 30(8):969-73. PubMed ID: 17702265 [TBL] [Abstract][Full Text] [Related]
11. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Bassetti C; Gugger M; Bischof M; Mathis J; Sturzenegger C; Werth E; Radanov B; Ripley B; Nishino S; Mignot E Sleep Med; 2003 Jan; 4(1):7-12. PubMed ID: 14592354 [TBL] [Abstract][Full Text] [Related]
12. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. Andlauer O; Moore H; Jouhier L; Drake C; Peppard PE; Han F; Hong SC; Poli F; Plazzi G; O'Hara R; Haffen E; Roth T; Young T; Mignot E JAMA Neurol; 2013 Jul; 70(7):891-902. PubMed ID: 23649748 [TBL] [Abstract][Full Text] [Related]